A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation
Open accessThe DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
This phase I study was designed to examine the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), the recommended dose (RD) for phase II, and the pharmacokinetics of NK105, a new polymeric micelle carrier system for paclitaxel (PTX). NK105 was administered as a 1-h intravenous infusion every 3 weeks, without antiallergic premedication. The starting dose was 10 mg m(-2), and the dose was escalated according to the accelerated titration method. Nineteen patients were recruited. The tumour types treated included pancreatic (n=11), bile duct (n=5), gastric (n=2), and colonic (n=1) cancers. Neutropenia was the most common haematological toxicity. A grade 3 fever developed in one patient given 180 mg m(-2). No other grades 3 or 4 nonhaematological toxicities, including neuropathy, was observed during the entire study period. DLTs occurred in two patients given 180 mg m(-2) (grade 4 neutropenia lasting for more than 5 days). Thus, this dose was designated as the MTD. Grade 2 hypersensitivity reactions developed in only one patient given 180 mg m(-2). A partial response was observed in one patient with pancreatic cancer. The maximum concentration (C(max)) and area under the concentration (AUC) of NK105 were dose dependent. The plasma AUC of NK105 at 150 mg m(-2) was approximately 15-fold higher than that of the conventional PTX formulation. NK105 was well tolerated, and the RD for the phase II study was determined to be 150 mg m(-2) every 3 weeks. The results of this phase I study warrant further clinical evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Some other paclitaxel polymeric micelle formulations, such NK105, were also reported to have lower toxicity in clinical trials compared to Taxol® [238].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [238]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a phase I trial of NK105, nineteen patients with various type of cancers (pancreatic, bile duct, gastric, and colonic) were recruited to examine the safety and PK of NK105. NK105 doses ranging from 10 mg/m2 to 180 mg/m2 was administered to patients without premedication. The MTD of NK105 was determined to be 180 mg/m2 due to dose limiting hematological toxicity (neutropenia). The PK profile of”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [238]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · cited 1×
“Tumour response was evaluated according to the Response Evaluation Criteria in Solid Tumors criteria (Therasse et al, 2000).”
MethodMatsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Self-citationTumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 2×
“These characteristics, which are unique to solid tumours, constitute the basis of the enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986; Maeda et al, 2000; Duncan, 2003).”
BackgroundSelf-citationThe dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269 · cited 2×
“These characteristics, which are unique to solid tumours, constitute the basis of the enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986; Maeda et al, 2000; Duncan, 2003).”
BackgroundGradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153 · cited 2×
“In this trial, Abraxane demonstrated significantly higher response rates, compared with standard PTX, and a significantly longer time to progression (Gradishar et al, 2005).”
BackgroundRowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924 · cited 1×
“However, the use of Cremophor EL is known to be associated with acute hypersensitivity reactions (Weiss et al, 1990; Rowinsky and Donehower, 1995; Kloover et al, 2004).”
BackgroundHypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174 · cited 1×
“However, the use of Cremophor EL is known to be associated with acute hypersensitivity reactions (Weiss et al, 1990; Rowinsky and Donehower, 1995; Kloover et al, 2004).”
BackgroundTaxol: A Novel Investigational Antimicrotubule Agent
Rowinsky, E. K., Cazenave, L. A., & Donehower, R. C. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.15.1247 · Cited by 1,090
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821 · cited 1×
“These preparations include Xyotax (polyglutamate-conjugated PTX; Singer et al, 2003; Boddy et al, 2005), Abraxane (PTX coated with albumin; Ibrahim et al, 2002; Deisai et al, 2003; Nyman et al, 2005), and Genexol-PM (a PTX micelle in which PTX has been simply solubilised; Kim et al, 2004).”
Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 705
Research works printed but not linked: 1
- Deisai N, Trieu V, Yao R (2003) Evidence of greater antitumor activity of Cremophor-free nanoparticle albumin-bound (nab) paclitaxel (Abraxane) compared to Taxol, role of a novel albumin transporter mechanism. 26th Annual San Antonio Breast Cancer Symposium San Antonio, TX
Cited by
Items 201–300 of 312
Moradi, V., Ketabi, S., Samadizadeh, M., Konoz, E., & Masnabadi, N. (2020) · Structural Chemistry · doi:10.1007/s11224-020-01658-x · Cited by 11
Recent Updates on Polymeric Micelles: A Review
Pawar, A., Kamdi, V., Alaspure, A., & Gangane, P. S. (2022) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2022.v73i01.010 · Cited by 11
Application of nanocarriers for paclitaxel delivery and chemotherapy of cancer
Malla, S., Neupane, R., Boddu, S. H. S., Abou-Dahech, M. S., Pasternak, M. A., Hussein, N. A., Ashby, C. R., Tang, Y., Babu, R. J., & Tiwari, A. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90951-8.00004-7 · Cited by 10
Wang, H., Zhang, J., Lv, G., Ma, J., Ma, P., Du, G., Wang, Z., Tian, J., Fang, W., & Fu, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114688 · Cited by 10
Kokuryo, D., Aoki, I., Yuba, E., Kono, K., Aoshima, S., Kershaw, J., & Saga, T. (2017) · Translational research · doi:10.1016/j.trsl.2017.04.001 · Cited by 10
Design, Synthesis, and Functionalization of Nanomaterials for Therapeutic Drug Delivery
Grandhi, T. S. P., & Rege, K. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-8739-0_9 · Cited by 10
New short interfering RNA-based therapies for glomerulonephritis
Shimizu, H., & Fujita, T. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.61 · Cited by 10
The Sojourn of Polymeric Micelles for Effective Brain Drug Delivery System
Kaur, P., Rajput, A., Singh, D., Singh, G., Mehra, A., Kaur, S., Bedi, N., & Arora, S. (2023) · Current Drug Delivery · doi:10.2174/1567201820666230413082352 · Cited by 9
Hafezi, M., & Sharif, F. (2015) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2015.09.005 · Cited by 9
Xiong, G., Jiang, C., Schätzlein, A. G., & Uchegbu, I. F. (2026) · Drug Delivery · doi:10.1080/10717544.2026.2614801 · Cited by 8
“In addition, a polymeric micelle-encapsulated PTX formulation (NK105) offers advantages such as higher drug loading and prolonged circulation time (Hamaguchi et al. 2007); however, its efficacy is also not superior to that of Taxol (Xiong et al. 2025a).”
Functionalized Nanomaterials In Pancreatic Cancer Theranostics And Molecular Imaging
Nagarajan, Y., Chandrasekaran, N., & Parvathi, V. D. (2024) · ChemistryOpen · doi:10.1002/open.202400232 · Cited by 8
Nano-based drug delivery system
Eskiler, G. G., Dıkmen, G., & Genc, L. (2015) · IAPC Publishing eBooks · doi:10.5599/obp.8.3 · Cited by 8
Targeted polymeric micellar systems for respiratory diseases
Virmani, R., & Pathak, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820658-4.00020-0 · Cited by 8
Biomarkers in Pancreatic Cancer as Analytic Targets for Nanomediated Imaging and Therapy
Grapa, C. M., MOCAN, L. C., Crișan, D., Florea, M., & Mocan, T. (2021) · Materials · doi:10.3390/ma14113083 · Cited by 8
“Micelle nanoparticles encapsulating paclitaxel were used in metastatic PC in a phase I trial, showing an improved anti-tumor activity due to the EPR effect [38].”
MethodCyclodextrins as non-viral vectors in cancer theranostics: A review
Qu, G., Xu, H., Ma, L., Feng, S., Li, Y., & Zhang, X. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143697 · Cited by 7
López-Méndez, T. B., Strippoli, R., Trionfetti, F., Calvo, P., Cordani, M., & González‐Valdivieso, J. (2022) · Springer eBooks · doi:10.1007/978-3-031-17831-3_12 · Cited by 7
Effects of block copolymer micelles on the pharmacokinetics of encapsulated drugs
Binkhathlan, Z., & Lavasanifar, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816200-2.00017-7 · Cited by 7
Yanagihara, K., Kubo, T., Mihara, K., Kuwata, T., Ochiai, A., Seyama, T., & Yokozaki, H. (2019) · Pancreas · doi:10.1097/mpa.0000000000001253 · Cited by 7
Wang, R., Zhang, Z., Wang, Q., Gu, P., Yang, Y., Wang, B., & Teng, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s580526 · Cited by 5
Nanomedicine-Mediated Combination Drug Therapy in Tumor
Chen, D., Xie, F., Sun, D., Yin, C., Gao, J., & Zhong, Y. (2017) · Open Pharmaceutical Sciences Journal · doi:10.2174/1874844901704010001 · Cited by 6
Apoptosis modulating nanochemotherapeutics in the treatment of cancer: Recent progress and advances
Singh, S., Sharma, N., Bansal, A. K., Kanojia, N., Sethi, S., Madan, J., & Sodhi, R. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815762-6.00006-8 · Cited by 6
Sialoganglioside Micelles for Enhanced Paclitaxel Solubility: In Vitro Characterization
Heredia, V., Alasino, R. V., Leonhard, V., Garro, A. G., Maggio, B., & Beltramo, D. M. (2015) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.10.029 · Cited by 6
Polymeric micelles in biomedical science
Bhawani, S. A., Ahmad, F. B., Ibrahim, M. N. M., & Yakout, A. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816504-1.00005-3 · Cited by 6
Implementation of Nanoparticles in Cancer Therapy
Bayır, E., Bilgi, E., & Şendemir, A. (2014) · Advances in chemical and materials engineering book series · doi:10.4018/978-1-4666-5824-0.ch018 · Cited by 5
Polymers in Drug Delivery: Concepts, Developments and Potential
Chen, R. (2013) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-94-007-6010-3_1 · Cited by 5
The Development and Achievement of Polymeric Nanoparticles for Cancer Drug Treatment
Lee, W., Loo, C., Young, P. M., Traini, D., & Rohanizadeh, R. (2017) · Springer eBooks · doi:10.1007/978-981-10-3647-7_2 · Cited by 5
Polymeric Micelles for Cancer‐Targeted Drug Delivery
Chen, H., Ge, Z., & Kataoka, K. (2014) · Wiley eBooks · doi:10.1002/9783527672752.ch4 · Cited by 4
Nanomedicine Magic Bullet for Human Cancer
Patnaik, S. (2016) · IGI Global eBooks · doi:10.4018/978-1-5225-0549-5.ch014 · Cited by 4
Nanomedicine: Size-Related Drug Delivery Applications, Including Periodontics and Endodontics
Ng, X. W., Mundargi, R. C., & Venkatraman, S. S. (2015) · Springer eBooks · doi:10.1007/978-3-319-13575-5_5 · Cited by 4
Perspectives on Clinical Translation of Smart Nanotherapeutics
Lee, J., & Lam, K. S. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.112 · Cited by 4
“The most common route of administration of nanoparticle drug is intravenously [20-22].”
BackgroundNanotechnology Applications in Breast Cancer
Tùng, B. T., Quynh, C. T. X., & Hong, N. K. (2022) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-9258-8.ch020 · Cited by 4
Advancing Small-Molecule Immunotherapy Through Polymeric Micelle Delivery
Suwal, K., Lee, H., Bashyal, S., Kim, D., Cho, H. J., & Hwang, D. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040418 · Cited by 3
Nanoparticle-Based Treatment and Imaging of Brain Tumors Potentials and Limitations
Sina, E. M., Israel, L. L., Bong-Seop, L., Hanson, C. J., Amatya, R., Chung, E. H., Ghani, M. A., Yen, A., Black, K. L., Perez, J. M., et al. (2024) · Springer eBooks · doi:10.1007/978-3-030-80662-0_23 · Cited by 3
Ethylcellulose- An Amazing Polymer For Anticancer Formulations
Mittal, V., Kriplani, P., & Guarve, K. (2023) · Current Applied Polymer Science · doi:10.2174/0124522716273253231129104511 · Cited by 3
Liu, B.-N., Gao, X., & Piao, Y. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i5.2181 · Cited by 3
The Role of Nanoparticles in Therapy of Real-World Patients with Pancreatic Cancer: A Scoping Review
Konstantinidis, I. K., Tsokkou, S., Katsikeros, D., Chatzikomnitsa, P., Papakonstantinou, M., Liampou, E., Toutziari, E., Giakoustidis, D. E., Bangeas, P., Papadopoulos, V. N., et al. (2025) · Cancers · doi:10.3390/cancers17101726 · Cited by 3
“NK105 exhibited a plasma area under the curve (AUC) 15 to 20 times higher than that of conventional paclitaxel, thereby augmenting the drug stability and improving tumor targeting [42].”
Role of new pharmaceutical technologies in enhancing the selectivity of antitumor drugs
Оборотова, Н. А., & Санарова, Е. В. (2013) · Russian Journal of General Chemistry · doi:10.1134/s1070363213120529 · Cited by 3
Nanotechnology in medicine-Nanomedicine
Gupta, S. R. N. (2016) · Journal of Pharmaceutical Care & Health Systems · Cited by 3
Polysaccharide-based Polyion Complex Micelles as New Delivery Systems for Hydrophilic Cationic Drugs
Soliman, G. M. (2009) · doi:10.71781/4636 · Cited by 3
Wang, Y., Zhang, Y., Wang, X., Zhao, W., Li, Q., Zhou, M., Liu, Y., Yi, X., He, J. I., Li, Y. P., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02712-8 · Cited by 2
Self-assemblies, dendrimers, and nanoparticles
Ambre, P., Gupta, C. R., Martis, E. A. F., & Coutinho, E. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821013-0.00009-x · Cited by 2
Nanomedicine in Cancer Treatment
Kim, J., & Cho, M. (2014) · Wiley eBooks · doi:10.1002/9781118856017.ch10 · Cited by 2
Multifunctional Polymeric Micelles for Drug Delivery and Therapeutics
Sawdon, A. J., & Peng, C. (2013) · Wiley eBooks · doi:10.1002/9781118636299.ch15 · Cited by 2
The initiatives for regulatory science researches of nanomedicines
Harashima, H., Akita, H., Sakai‐Kato, K., Ishii, T., Matsumura, Y., & Kataoka, K. (2014) · Drug Delivery System · doi:10.2745/dds.29.217 · Cited by 2
Self-citationDrug Delivery Vehicles from Stimuli‐Responsive Block Copolymers
Kulkarni, P., & Mallik, S. (2018) · Wiley eBooks · doi:10.1002/9781119156253.ch7 · Cited by 2
Preparation and Properties of Antitumor Drug Based on Lipid Derivative of Sarcolysin
Tereshkina, Y. A., Sanzhakov, M. A., Kostryukova, L. V., Korotkevich, E., Chistov, A. A., Tikhonova, E. G., Prozorovsky, V. N., & Ipatova, O. M. (2019) · Biomedical Chemistry Research and Methods · doi:10.18097/bmcrm00098 · Cited by 2
Коbylinska, L. I., Mitina, N., Zaichenko, A., & Стойка, Р. С. (2021) · Springer eBooks · doi:10.1007/978-3-030-76235-3_5 · Cited by 2
Development and evaluation of curcumin-loaded Pluronic F127 nanoformulation
Shamsi, S. (2015) · UWA Profiles and Research Repository (University of Western Australia) · Cited by 2
Patankar, N. A. (2010) · cIRcle (University of British Columbia) · doi:10.14288/1.0071510 · Cited by 2
Caron, W. P. (2013) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/c0yq-0a71 · Cited by 2
Π-π Stacked Polymeric Micelles as Carriers of Anticancer Therapeutics for Hematological Malignancies
Varela-Moreira, A. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/145 · Cited by 2
IJRDO - Journal Of Biological Science
(2024) · doi:10.69980/bs.v12i1 · Cited by 2
Yu, Y., Li, X., Zhao, Z., Bu, F.-Z., Zhiyong, W., & Li, Y. (2025) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2025.2581141 · Cited by 1
“…phagocytosed and cleared in the body, which is beneficial to staying in the body long enough and gradually accumulating in the desired area [17,18]. thus, the nanomicelles by packing Flu into Peg–Pcl with amphi-philic character have been applied to protect Flu for realizing the sustained…”
Clinical development of anticancer agents incorporating micelles in oncological treatment
Matsumura, Y. (2013) · Drug Delivery System · doi:10.2745/dds.28.215 · Cited by 1
Self-citationHai-wen, Z., Li-qun, W., & Jiang, H. (2013) · Acta Polymerica Sinica · doi:10.3724/sp.j.1105.2012.12115 · Cited by 1
Nanomedicine Magic Bullet for Human Cancer
Patnaik, S. (2014) · Advances in chemical and materials engineering book series · doi:10.4018/978-1-4666-6363-3.ch009 · Cited by 1
Clinical trials of NK105, a paclitaxel incorporating micellar nanoparticle formation
Kato, K. (2009) · Drug Delivery System · doi:10.2745/dds.24.28 · Cited by 1
Self-citationA clinical trial can determine the course of DDS development
Matsumura, Y. (2014) · Drug Delivery System · doi:10.2745/dds.29.39 · Cited by 1
Self-citationTranslational research of DDS based on polymeric micelles
Nishiya, T., Matsumura, Y., & Kataoka, K. (2011) · Folia Pharmacologica Japonica · doi:10.1254/fpj.137.75 · Cited by 1
Self-citationPolymeric Nanosystems for Integrated Image-Guided Cancer Therapy
Singh, A., Iyer, A. K., & Amiji, M. M. (2014) · Frontiers in nanobiomedical research · doi:10.1142/9789814520652_0006 · Cited by 1
Rational Design of Polymeric Micelle for Cancer Therapy
Huang, Y., Sun, J., & Li, S. (2016) · Advances in medical technologies and clinical practice book series · doi:10.4018/978-1-5225-0751-2.ch012 · Cited by 1
Current status of nanomedicine for breast cancer treatment
Fraguas‐Sánchez, A. I., Martín‐Sabroso, C., Fernández-Carballido, A. M., & Torres‐Suárez, A. I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824476-0.00014-0 · Cited by 1
Gaucher, G. (2009) · doi:10.71781/4932 · Cited by 1
Ma, P. (2012) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/wjrm-8p74 · Cited by 1
Novel gel-associated drug loaded nanocarriers for intratumoural delivery
Štaka, I. (2018) · Nottingham ePrints (University of Nottingham) · Cited by 1
Development of block copolymer based nanocarriers for the solubilization and delivery of valspodar
Binkhathlan, Z. (2011) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r35t2f · Cited by 1
Poly(2-oxazoline)s as new drug delivery systems
He, Z. (2015) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/er9f-gq81 · Cited by 1
Miller, K., & Satchi‐Fainaro, R. (2008) · Wiley eBooks · doi:10.1002/9780470048672.wecb462 · Cited by 1
TARGETED THERAPY FOR LIVER FIBROSIS AND CANCER
Zhang, Y. (2014) · D-Scholarship@Pitt (University of Pittsburgh)
POLYMERIC MICELLES AS IMAGING AGENTS AND DRUG DELIVERY SYSTEMS
Zhao, J., & Li, C. (2013) · Wiley eBooks · doi:10.1002/9781118356845.ch12
Bobe, I., Harada, M., & Ichiro, N. (2013) · Wiley eBooks · doi:10.1002/9781118451915.ch6
Polymeric micelles for solubilization and targeting of hydrophobic drugs
Miller, T. (2013) · University of Regensburg Publication Server (University of Regensburg) · doi:10.5283/epub.25345
Investigations into Drug Delivery to the Eye: Nanoparticle Comparisons
Al‐Ebini, Y. (2014) · University of Hertfordshire Research Archive (University of Hertfordshire) · doi:10.18745/th.13891
Carrier-Mediated and Targeted Cancer Drug Delivery
Zamboni, W. C., & La-Beck, N. M. (2011) · Humana Press eBooks · doi:10.1007/978-1-61779-397-4_21
Matsumura, Y. (2010) · Oleoscience · doi:10.5650/oleoscience.10.25
Self-citationClinical development of nano-DDS
Matsumura, Y. (2011) · Drug Delivery System · doi:10.2745/dds.26.20
Self-citationAnticancer agent-incorporating immunomicelles
Yamamoto, Y., Hamaguchi, T., & Matsumura, Y. (2015) · Drug Delivery System · doi:10.2745/dds.30.10
Self-citationApplications of Janus and Anisotropic Particles for Drug Delivery
Poon, Z., & Hammond, P. T. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849735100-00257
Nanoparticle-Based Treatment and Imaging of Brain Tumors: Potentials and Limitations
Bong-Seop, L., Hanson, C. J., Amatya, R., Chung, E. H., Ghani, M., Yen, A., Black, K. L., & Yu, J. S. (2013) · CRC Press eBooks · doi:10.1201/b15274-26
Toxicology in the Nanoscale World
(2015) · CRC Press eBooks · doi:10.1201/b18211-8
Microscopic Mass Spectrometry for the Precise Design of Drug Delivery Systems
Matsumura, Y., & Yasunaga, M. (2016) · Fundamental biomedical technologies · doi:10.1007/978-3-319-43525-1_13
Self-citationMicrofluidic synthesis of drug-loaded block copolymer nanoparticles and its effect on drug delivery
Cao, Y. (2016) · UVic’s Research and Learning Repository (University of Victoria)
Systemic Drug Delivery in Gastric Cancer
Li, R., & Yang, M. (2017) · Springer eBooks · doi:10.1007/978-981-10-3978-2_14
Mikhail, A. S. (2013) · TSpace (University of Toronto)
Nanopartículas poliméricas autoensambladas y bioactivas para el tratamiento del cáncer
Palao‐Suay, R. (2016) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Arborescent Polypeptides for Sustained Drug Delivery Applications
Alsehli, M. (2017) · UWSpace (University of Waterloo)
Hoang, B. (2014) · TSpace (University of Toronto)
Wang, Z. (2017) · Human Biology
Development of polymer and lipid based nano-delivery systems for targeted cancer chemotherapy
Shahin, M. (2012) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3vt1gz32
PRINT® nanoparticle parameters to improve docetaxel PK/PD
Chu, K. S. (2013) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/ybxx-7b26
Alsuraifi, A. (2018) · Keele Research Repository (Keele University)
Development of multi-functionalized polymeric carriers for delivery of anticancer drug combinations
Phuoc, D. H. H. (2013) · National University of Singapore
Cossío, U. (2018) · Communities in ADDI (Universidad del Pais Vasco)
Anticancer Agents: Drug Carrier Systems
Koide, H., Asai, T., Shimizu, K., & Oku, N. (2015) · Taylor & Francis eBooks · doi:10.1081/e-ebpp-120052266
The Current Status of Cancer Drug Delivery Systems and Future Directions
Matsumura, Y., & Tarin, D. (2019) · Springer eBooks · doi:10.1007/978-4-431-56880-3_14
Self-citationImplementation of Nanoparticles in Cancer Therapy
Bayır, E., Bilgi, E., & Şendemir, A. (2016) · IGI Global eBooks · doi:10.4018/978-1-5225-1762-7.ch047
Bhattu, M., Pal, N., Kapil, S., Kathuria, D., & Verma, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95325-2.00019-5
Коbylinska, L. I., Mitina, N., Zaichenko, A., & Стойка, Р. С. (2024) · Springer eBooks · doi:10.1007/978-3-031-61877-2_5
A review on polymer micelles as drug carriers
Kadlag, P., Salave, G. R., Aher, P. R., & Jadhav, A. D. (2025) · Journal of Pharmacognosy and Phytochemistry · doi:10.22271/phyto.2025.v14.i3c.15374
“…understanding of Polymer micelles utilized as carriers for pharmaceuticals presented in this review underscores their significant impact on the field of pharmaceutical sciences and highlights the exciting opportunities they offer for advancing drug delivery and improving patient outcomes [60] .”
Metadata
- Authors
- Hamaguchi, T., Kato, K., Yasui, H., Morizane, C., Ikeda, M., Ueno, H., Muro, K., Yamada, Y., Okusaka, T., Shirao, K., Shimada, Y., Nakahama, H., & Matsumura, Y.
- Affiliations
- National Cancer Center Hospital (JP)
- National Cancer Center Hospital East (JP)
- Corresponding author
- Hamaguchi, T
- ORCID
- Venue
- British Journal of Cancer
- Published
- 2007-06-26
- Volume
- 97
- Issue
- 2
- Pages
- 170-176
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2360299
- OpenAlex
- W1990869510
- Cited by
- 290
- References
- 24
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 10 · 2023: 5 · 2022: 13 · 2021: 10 · 2020: 16 · 2019: 14 · 2018: 13 · 2017: 15 · 2016: 18 · 2015: 23 · 2014: 29 · 2013: 29 · 2012: 22
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- paclitaxel, polymeric micelles, maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, neutropenia, hypersensitivity, pancreatic cancer, cholangiocarcinoma, gastric cancer, colon cancer, accelerated titration
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Phytogenic, Digestive System Neoplasms, Female, Humans, Male, Micelles, Middle Aged, Tomography, X-Ray Computed, Paclitaxel, Maximum Tolerated Dose, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.